Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33287
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHegi-Johnson, Fiona-
dc.contributor.authorRudd, Stacey E-
dc.contributor.authorWichmann, Christian W-
dc.contributor.authorAkhurst, Tim-
dc.contributor.authorRoselt, Peter-
dc.contributor.authorSursock, Sandra-
dc.contributor.authorTrinh, Jenny-
dc.contributor.authorJohn, Thomas-
dc.contributor.authorDevereux, Lisa-
dc.contributor.authorDonnelly, Paul S-
dc.contributor.authorHicks, Rodney J-
dc.contributor.authorScott, Andrew M-
dc.contributor.authorSteinfort, Daniel-
dc.contributor.authorFox, Stephen-
dc.contributor.authorBlyth, Benjamin-
dc.contributor.authorParakh, Sagun-
dc.contributor.authorHanna, Gerard G-
dc.contributor.authorCallahan, Jason-
dc.contributor.authorBurbury, Kate-
dc.contributor.authorMacManus, Michael-
dc.date2023-
dc.date.accessioned2023-07-14T02:52:25Z-
dc.date.available2023-07-14T02:52:25Z-
dc.date.issued2023-11-01-
dc.identifier.citationInternational Journal of Radiation Oncology, Biology, Physics 2023-11-01; 117(3)en_US
dc.identifier.issn1879-355X-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/33287-
dc.description.abstractImmunoPET is a multicenter, single arm, phase 0-1 study of 89Zr-DFO-Sq-durvalumab (89Zr-durvalumab), a novel PET tracer, designed to interrogate the expression of PD-L1 in patients with NSCLC. Clinically relevant findings from phase 0 are presented here. Phase 0 was designed to investigate tracer biodistribution and safety in patients with metastatic NSCLC with PD-L1 expression >25%. After 60MBq/70kg 89Zr-durvalumab infusion, PET/CT images were acquired at days 0, 1, 3 or 5 ± 24h. Baseline FDG PET/CT was performed prior to PD-L1 PET imaging. All five patients recruited to phase 0 completed the full imaging protocol. The only reported adverse event was a transient asymptomatic increase in respiratory rate. At the time of PD-L1 imaging, two patients were in complete remission on FDG-PET after treatment with osimertinib and pembrolizumab; neither showed PD-L1 tracer uptake in previous tumor sites. All three patients with active tumor had received radiotherapy to some or all disease sites prior to PD-L1 imaging. With the exception of a single disease site, specific uptake of 89Zr-durvalumab uptake was seen in tumours, with increasing uptake in tumor seen up to Day 5 post-injection. Patient 1, who had multiple metastases, including brain and bone, showed more intense 89Zr-durvalumab uptake in recently irradiated bone lesions than un-irradiated lesions and uptake was also observed in treated brain metastases.. One patient, who experienced rapid growth of a single lung lesion that had acquired resistance to pembrolizumab, showed no significant 89Zr-durvalumab in that lesion, despite recent radiotherapy. In patient 5, 89Zr-durvalumab uptake was observed in the viable rim of a large, recently irradiated adrenal oligometastasis. 89Zr- durvalumab imaging was safe and detected known viable tumor at multiple sites. Recently irradiated tumours showed the highest uptake and in another, a single site of immunotherapy resistant disease showed minimal tracer uptake. PD-L1 imaging may have utility in patients with NSCLC treated with radiotherapy.en_US
dc.language.isoeng-
dc.titlePD-L1 PET imaging in patients with NSCLC: Preliminary results of the ImmunoPET Phase 0 study.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleInternational Journal of Radiation Oncology, Biology, Physicsen_US
dc.identifier.affiliationRadiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationSchool of Chemistry and Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen_US
dc.identifier.affiliationSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia; Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationCancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationRadiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia; The Department of Medicine, St Vincent's Medical School, University of Melbourne, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationSchool of Chemistry and Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationThe Department of Medicine, St Vincent's Medical School, University of Melbourne, Melbourne, Victoria, Australia; The Department of Medicine, Central Medical School, the Alfred Hospital, Monash University, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia; School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia; Department of Molecular Imaging and Therapy, Austin Health, and The University of Melbourne, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationSir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia; Anatomical Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationMolecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationHaematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.en_US
dc.identifier.doi10.1016/j.ijrobp.2023.05.019en_US
dc.type.contentTexten_US
dc.identifier.pubmedid37406824-
local.name.researcherJohn, Thomas-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

46
checked on Mar 4, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.